Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance

Yasu Imai, Satomi Tsukahara, Sakiyo Asada, and Yoshikazu Sugimoto

Division of Molecular Biotherapy, Japanese Foundation for Cancer Research, Tokyo, Japan, and Department of Chemotherapy, Kyoritsu University of Pharmacy, Tokyo, Japan

ABSTRACT

Breast cancer resistance protein (BCRP), also called ABCG2, confers resistance to anticancer agents such as 7-ethyl-10-hydroxycamptothecin (SN-38), mitoxantrone, and topotecan. We found previously that sulfated estrogens are physiologic substrates of BCRP. Flavonoids with very weak estrogenic activities are called phytoestrogens. In this study, we show that phytoestrogens/flavonoids, such as genistein, naringenin, acacetin, and kaempferol, potentiated the cytotoxicity of SN-38 and mitoxantrone in BCRP-transduced K562 (K562/BCRP) cells. Some glycosylated flavonoids, such as naringenin-7-glucoside, also effectively inhibited BCRP. These flavonoids showed marginal effect on the drug sensitivity of K562 cells. Genistein and naringenin reversed neither P-glycoprotein-mediated vincristine resistance nor multidrug resistance-related protein 1-mediated VP-16 resistance. Genistein and naringenin increased cellular accumulation of topotecan in K562/BCRP cells. K562/BCRP cells also accumulated less [3H]genistein than K562 cells. [3H]genistein transport in the basal-to-apical direction was greater in BCRP-transduced LLC-PK1 (LLC/BCRP) cells, which express exogenous BCRP in the apical membrane, than in parental cells. Fumitremorgen C abolished the increased transport of [3H]genistein in LLC/BCRP cells compared with parental cells. TLC analysis revealed that genistein was transported in its native form but not in its metabolized form. These results suggest that genistein is among the natural substrates of BCRP and competitively inhibits BCRP-mediated drug efflux. The results have two important clinical implications: (a) flavonoids and glycosylated flavonoids may be useful in overcoming BCRP-mediated drug resistance in tumor cells; and (b) coadministration of flavonoids with BCRP-substrate antitumor agents may alter the pharmacokinetics and consequently increase the toxicity of specific antitumor agents in cancer patients.

INTRODUCTION

Multidrug-resistance (MDR; Ref. 1) is a phenomenon in which cancer cells display cross-resistance to structurally unrelated drugs (2). During chemotherapy, cancer cells displaying an MDR phenotype gradually appear in the course of repeated chemotherapeutic drug regimens, and patients displaying MDR phenotype eventually become nonresponsive to these treatments. Breast cancer resistance protein (BCRP), also called ABCG2, is a half-transporter with a molecular logic substrates of BCRP; and (ii) drug efflux. The results have two important clinical implications: (a) flavonoids and glycosylated flavonoids may be useful in overcoming BCRP-mediated drug resistance in tumor cells; and (b) coadministration of flavonoids with BCRP-substrate antitumor agents may alter the pharmacokinetics and consequently increase the toxicity of specific antitumor agents in cancer patients.

MATERIALS AND METHODS

Reagents. Flavonoids used in these experiments were purchased from Funakoshi (Tokyo, Japan). Anti-P-glycoprotein monoclonal antibody C219 was purchased from Centocor (Malvern, PA), and anti-MRP1 monoclonal antibody MRPlp6 was obtained from Nichirei (Tokyo, Japan). [3H]Genistein (5 Ci/mmol) was obtained from American Radiolabeled Chemicals (St. Louis, MO).

Establishment of K562/BCRP, LLC/BCRP, K562/MDR, and KB/MPR Cell Lines. K562 human leukemic cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37°C in 5% CO2. K562/BCRP cells were established by transduction of K562 cells with HaBCRP retrovirus, bearing human BCRP cDNA, and subsequent selection with 20 ng/ml SN-38 for 5 days. LLC-PK1 cells, epithelial cells of the porcine kidney, were cultured in M199 medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum. LLC/BCRP cells were established by the transduction of LLC-PK1 cells with HaBCRP retrovirus and subsequent selection with increasing doses of mitoxantrone (2, 4, and 8 nM) for 17 days. The resulting mixed population of drug-resistant cells was used in this study as described previously (8, 11). K562/MDR cells were established by transduction of K562 cells with HaMDR retrovirus containing human MDR1 cDNA, and this was followed by selection using 4 ng/ml vincristine for 7 days (12). KB-3–1 human epidermoid carcinoma cells were cultured in DMEM supplemented with 10% fetal bovine serum at 37°C in 5% CO2. KB/MPR cells were established by introduction of the pl3U-MRP1 construct bearing human MRP1 cDNA into KB–3–1 cells, followed by selection with increasing concentrations of doxorubicin (13). Expression of BCRP in K562/BCRP and LLC/BCRP cells, expression of P-glycoprotein in K562/MDR, and expression of MRP1 in KB/MPR cells were confirmed by Western blot analysis with the anti-BCRP polyclonal antibody 3488, anti-P-glycoprotein monoclonal antibody C219, and anti-MRP1 monoclonal antibody MRPlp6, respectively. The Western blot analysis procedure is described elsewhere (11).

Cell Growth Inhibition Assay. The effects of specific compounds on the sensitivity of cells to SN-38 and mitoxantrone were evaluated by measuring...
cell growth inhibition after incubation at 37°C for 5 days in the absence or presence of various concentrations of anticancer drugs in combination with the specific chemicals being examined. Cell numbers were determined using a Coulter counter (Sysmex, Kobe, Japan). IC₅₀ values (drug dosages that cause 50% inhibition of cell growth) were determined from growth inhibition curves.

**Intracellular Topotecan Uptake.** The effects of specific compounds on the cellular accumulation of topotecan were determined by flow cytometry. Cells (5 × 10⁵) were incubated with 20 μM topotecan for 30 min at 37°C in the absence or presence of modifying agents, washed in ice-cold PBS, and subjected to fluorescence analysis using FACSCalibur (Becton-Dickinson, San Jose, CA).

**Cellular [³H]Genistein Accumulation in K562/BCRP Cells.** Either K562 or K562/BCRP cells (2 × 10⁵) were incubated with 30 nM [³H]genistein for 0, 1, 2, or 4 h at 37°C. The cells then were washed with ice-cold PBS, dissolved in 100 μl PBS plus 400 μl Soluene-350 (Packard, Downer’s Grove, IL), and mixed with 5 μl ACS II scintillation mixture (Amersham, Piscataway, NJ). Radioactivity levels were measured using a scintillation counter (Beckman, Fullerton, CA).

**Transcellular Transport Assay of [³H]Genistein and Silica Gel TLC of Transported Compounds.** Details of the experimental procedure are described previously (8). Briefly, exponentially growing LLC-PK1 and/or LLC/BCRP cells were plated on 3-μm pore Transwell 3414 filters (Corning Costar, Cambridge, MA) at a density of 2.4 × 10⁵ cells/well and cultured for 3 days. Culture medium in the upper and lower wells was replaced with 2 ml of serum-free M199 medium 1.5 h before beginning the experiments. When needed, fumitremorgin C was added to the apical and basal side medium at this time (14). The medium in either the upper or lower well was then replaced with 2 ml of medium containing [³H]-labeled indin and/or [³H]-labeled genistein. The cells were incubated at 37°C in 5% CO₂, and 50 μl of the medium from the opposite side were sampled at 1, 2, and 4 h following the addition of radiolabeled compounds. The radioactivity of each sample was measured by liquid scintillation counting and expressed as a percentage fraction of the total radioactivity before incubation. All of the data were presented as mean values with SD of triplicate determinations.

**Statistical Analysis.** The two-sided unpaired Student’s t test was used to evaluate the statistical significance of the differences between the two sets of data. The differences were considered significant when P < 0.05.

**RESULTS**

**Characteristics of K562/BCRP, LLC/BCRP, K562/MDR, and KB/MRP Cells.** Among the four drug-resistant cell lines used in this study, K562/BCRP cells expressed BCRP but not P-glycoprotein or MRP1. LLC/BCRP cells expressed BCRP. K562/MDR cells expressed P-glycoprotein but not BCRP or MRP1, and KB/MRP cells expressed MRP1 but not BCRP or P-glycoprotein (Fig. 1). Expression of BCRP, P-glycoprotein, or MRP1 was not detected in parental K562 cells and KB-3–1 cells.

K562/BCRP cells showed significantly higher resistance to SN-38 and mitoxantrone than K562 cells (Table 1). LLC/BCRP cells were five to six times more resistant to SN-38 and mitoxantrone than parental LLC-PK1 cells as described previously (8). K562/MDR cells showed significantly higher resistance to vincristine than K562 cells, and KB/MRP cells were significantly more resistant to VP-16 than KB-3–1 cells (Table 1). Protein expression and drug-resistance levels in each resistant cell line were stable for at least 2 months.

**Reversal of BCRP-Mediated Drug Resistance by Flavonoids.** Estrone, 17β-estradiol, estrogen agonists, and estrogen antagonists reverse BCRP-mediated drug resistance. In the present study, we examined the potential reversal effects of phytoestrogens/flavonoids because they have been shown to have weak estrogenic activities (10). Structures of representative flavonoids are shown in Fig. 2. We first examined the effects of representative phytoestrogens, genistein and naringenin, on drug resistance in K562/BCRP cells (Fig. 3, A–C). Reversal indexes (ratios of IC₅₀ measurements in the absence of reversing agents divided by levels in the presence of reversing agents) of 3 μM (10 μM) genistein for SN-38 and mitoxantrone were 7.23 ± 0.35 (16.4 ± 0.56) and 6.28 ± 0.51 (11.7 ± 0.40), respectively. In addition, reversal indexes of 3 μM (10 μM) naringenin for SN-38 and mitoxantrone were 5.94 ± 0.26 (15.2 ± 0.92) and 3.42 ± 0.27 (10.6 ± 0.30), respectively. The reversal effects of genistein and naringenin proved to be greater than estrone. Analysis then was extended to other flavonoids, many of which reversed BCRP-mediated SN-38 resistance at a fixed concentration of 3 μM (Fig. 4). The flavones acacetin, apigenin, chrysin, diosmetin, and luteolin and the flavonoids kaempferide and kaempferol displayed strong reversal effects (Fig. 3, D and E, and Fig. 4). Reversal indexes of 1 μM (3 μM) acacetin for SN-38 and mitoxantrone were 15.2 ± 1.10 (21.4 ± 0.34) and 9.89 ± 0.27 (9.71 ± 0.81), respectively. Reversal indexes of 1 μM (3 μM) kaempferol for SN-38 and 4347
mitoxantrone were 9.96 ± 0.38 (21.5 ± 0.53) and 10.6 ± 0.99 (14.2 ± 0.95), respectively. However, the flavonoids did not show growth-inhibitory effects on K562 cells under these experimental conditions. K562/BCRP cells treated with estrone or flavonoids, such as genistein, naringenin, and acacetin, for 5 days expressed similar amounts of BCRP as compared with control K562/BCRP cells (Fig. 5). This result suggested that flavonoids sensitized K562/BCRP cells to SN-38 and mitoxantrone not by reducing BCRP expression but by inhibiting BCRP function. We then examined the effects of glycosylated flavonoids on the drug-resistance properties of K562/BCRP cells. Although most glycosylated flavonoids had little effect on BCRP-mediated drug resistance, some glycosides, such as naringenin-7-glucoside and luteolin-4′-O-glucoside, displayed moderate reversal activity (Fig. 6). Reversal indexes of 3 μM (10 μM) naringenin-7-glucoside for SN-38 and mitoxantrone were 5.70 ± 0.16 (14.7 ± 0.53) and 5.17 ± 0.23 (9.44 ± 0.42), respectively.

Additional studies showed that the reversal of MDR by genistein and naringenin was specific to BCRP because they did not show any reversal effects on either P-glycoprotein-mediated vincristine resistance or MRP1-mediated VP-16 resistance (Fig. 7).

Intracellular Topotecan Uptake and Cellular [3H]Genistein Accumulation in K562/BCRP Cells. To address whether reversal of BCRP-mediated drug resistance by flavonoids might be associated with the inhibition of BCRP-mediated drug efflux, the cellular accumulation of topotecan was evaluated in the absence or presence of specific flavonoids by flow cytometric analysis. Intracellular accumulation of topotecan increased in the presence of genistein or naringenin in a dose-dependent manner in K562/BCRP cells (Fig. 8), whereas these levels were not altered in K562 cells (data not shown). The results indicate that these flavonoids reverse anticancer drug resistance mediated by BCRP.

Fig. 3. Reversal effects of estrone and phytoestrogens/flavonoids on breast cancer resistance protein (BCRP)-mediated antitumor drug resistance. K562 (open symbols) and K562/BCRP (closed symbols) cells were cultured for 5 days in the absence (circle) or presence of 0.3 μM (lozenge), 1 μM (square), 3 μM (triangle), and 10 μM (inverted triangle) of the specific compounds indicated under increasing concentrations of antitumor drugs. A, estrone. B, genistein. C, naringenin. D, acacetin. E, kaempferol. Antitumor agents are SN-38 (N-1) and mitoxantrone (N-2; N, A–E). Data points are measurements of the average ± SD from triplicate determinations. Cell numbers were determined with a cell counter.

Fig. 4. Inhibitory effects of phytoestrogens/flavonoids on breast cancer resistance protein (BCRP)-mediated SN-38 resistance. K562 and K562/BCRP cells were cultured for 5 days in the absence or presence of 3 μM compound with increasing concentrations of SN-38. Cell numbers were determined using a cell counter, and IC₅₀ values then were measured. Open bar, no inhibitor. Dotted bar, treatment with flavonoids. The degree of resistance is the ratio of IC₅₀ values of the cells to that of K562 cells under the indicated experimental conditions.

Fig. 5. Western blot analyses of breast cancer resistance protein (BCRP) expression in K562/BCRP cells treated with estrone or flavonoids for 5 days. K562 and K562/BCRP cells were incubated for 5 days in the absence or presence of indicated concentrations of compounds. Cell lysates (20 μg/lane) were used for quantitative analyses of BCRP expression. Expression of α-tubulin was presented as an internal control.
Fig. 6. Inhibitory effects of glycosylated flavonoids on breast cancer resistance protein (BCRP)-mediated drug resistance. A, inhibitory effects of glycosylated flavonoids on BCRP-mediated SN-38 resistance. K562 and K562/BCRP cells were cultured for 5 days in the presence or absence of 3 μM flavonoids with increasing concentrations of SN-38. Cell numbers were measured with a cell counter, and IC₅₀ values then were determined. The degree of resistance is the ratio of IC₅₀ values of the cells to that of K562 cells under the indicated experimental conditions. Open bar, no inhibitor. Dotted bar, treatment with flavonoids. Solid bar, treatment with glycosylated flavonoids. Naringenin-G₁, naringenin-7-glucoside; Apigenin-G₁, apigenin-7-glucoside (chrysophanol); Diosmetin-G₂, diosmetin-7-β-rutinoside (Diosmin); Luteolin-G₃, luteolin-4′-O-glucoside; Kaempferol-G₄, kaempferol-3-glucoside; Kaempferol-G₅, kaempferol-7-O-neohesperidose; Quercetin-G₆, quercetin-3-arabinoglucoside (pelletoside); and Quercetin-G₇, quercetin-3-rutinoside (Rutin). B, reversal effects of naringenin-7-glucoside on BCRP-mediated drug resistance. K562 (open symbol) and K562/BCRP (closed symbol) cells were cultured for 5 days in the presence (circle) or absence of 3 μM (triangle) and 10 μM (inverted triangle) naringenin-7-glucoside with increasing concentrations of antitumor drugs. Data points are the average ± SD from triplicate determinations. Cell numbers were determined by a cell counter.

 resistance by increasing the cellular levels of anticancer drugs in BCRP-expressing cells.

To examine whether flavonoids themselves are transported by BCRP, the intracellular accumulation of [³H]genistein in K562 and K562/BCRP cells also was examined. K562/BCRP cells accumulated a significantly smaller amount of [³H]genistein than K562 cells, suggesting that there is BCRP-mediated efflux of genistein out of the cells (Fig. 9).

Transcellular Transport of [³H]Genistein. BCRP-mediated transport of genistein was examined by transcellular transport assays using LLC/BCRP cells, which express BCRP in the apical membrane (8). The paracellular fluxes monitored by [¹⁴C]inulin appearance in the other side of the growth chambers were <1% of the total radioactivity/h. Basal-to-apical transport (secretion) of [³H]mitoxantrone, a BCRP substrate, was greater in LLC/BCRP cells than that in LLC-PK1 cells (8). In the present study, secretion of [³H]genistein in LLC/BCRP cells also proved to be greater than that in LLC-PK1 cells, whereas apical-to-basal transport (reabsorption) of [³H]genistein in LLC/BCRP cells was reduced compared with LLC-PK1 cells (Fig. 10). However, in the presence of 3 μM fumitremorgin C, secretion and reabsorption of [³H]genistein were at similar levels between LLC-PK1 and LLC/BCRP cells.

Our previous study demonstrated that [³H]estrone was converted to [³H]estrone sulfate in LLC-PK1 cells and that the latter was exported by BCRP (8). Therefore, transported radioactivity over the apical membrane of the cells was analyzed by silica gel TLC. [³H]genistein

Fig. 7. Reversal effects of genistein and naringenin on either P-glycoprotein- or MRP1-mediated antitumor drug resistance. Parental cells (open symbol) and transfected cells (closed symbol) were cultured for 5 days in the absence (circle) or presence of 3 μM (triangle) or 10 μM (inverted triangle) compounds with increasing concentrations of the antitumor agents. Cell numbers were determined using a cell counter. A-1, effect of genistein on the vincristine sensitivity of K562 and K562/MDR cells. A-2, effect of genistein on the VP-16 sensitivity of KB-3-1 and KB/MRP cells. B-1, effect of naringenin on the vincristine sensitivity of K562 and K562/MDR cells. B-2, effect of naringenin on the VP-16 sensitivity of KB-3-1 and KB/MRP cells. Data points are the average ± SD from triplicate determinations.

Fig. 8. Effects of estrone and flavonoids on the cellular uptake of topotecan in K562/BCRP cells. Cells were incubated with (bold line) or without (dotted line) 20 μM topotecan in the absence or presence of the indicated compound. Uptake of topotecan was measured using fluorescence-activated cell sorter. A fluorescence peak shift to the right was observed in K562 cells. In K562/BCRP cells, a fluorescence peak shift was not observed in the absence of estrone or flavonoids, but a fluorescence peak shift to the right indicating cellular uptake of topotecan occurred in a dose-dependent manner of the compounds.
migrated at Rf = 0.8 (segment 11). TLC of transported radioactivity after 4-h incubation showed that almost all of the [3H]genistein was transported in its native form and migrated at Rf = 0.8 (segment 11) under these experimental conditions. Secretion of [3H]genistein was significantly greater in LLC/BCRP cells than that in LLC-PK1 cells (Fig. 11), indicating that genistein itself is directly transported by BCRP. In a separate experiment, when [3H]genistein was incubated with LLC-PK1 cells for 24 h, >80% of the radioactivity shifted to Rf = 0.12–0.21 (segment 3–4) and approximately 10% shifted to Rf = 0.38–0.47 (segment 6–7), in which metabolites of genistein were expected to exist (data not shown). However, only small amounts of such metabolites were found in the 4-h transport assay (Fig. 11).

Fig. 10. Transcellular transport of [3H]genistein by breast cancer resistance protein (BCRP). Cells (2 × 10^6) were plated on 3-μm pore filters and cultured for 3 days. The apical and the basal sides of the medium were replaced with 2 ml serum-free medium 1.5 h before beginning the experiment. When required, 3 mM fumitremorgin C was added to the apical and basal side medium at this time. [3H]genistein (30 nM) for 0, 1, 2, or 4 h at 37°C. After washing, the cells were dissolved in 100 μl PBS and 400 μl Soluene-350 and mixed with 5 ml ACS II scintillation mixture. Radioactivity was measured using a scintillation counter. The data are mean ± SD from triplicate determinations.

DISCUSSION

Estriol and 17β-estradiol are the first endogenous compounds that were shown to exert strong BCRP-reversing activity (7). Synthesized estrogen agonists and antagonists also showed strong reversing activity of BCRP-mediated drug resistance (9). Therefore, we extended our studies to natural estrogenic compounds in the search for BCRP inhibitors.

Isoflavones derived from soybean, such as genistein and daidzein, constitute a subset of flavonoids that have been reported to have weak estrogenic activity (10). In addition, chemical structures of isoflavones resemble those of estrone and 17β-estradiol (Fig. 2). Naringenin, a flavanone contained in grapefruit juice, also resembles 17β-estradiol in chemical structure, albeit to a lesser extent than isoflavone (Fig. 2). Flavonoids are remarkably safe nutrients, being the most abundant polyphenolic compounds present in the human diet in fruits, vegetables, and plant-derived beverages such as tea and red wine (15). Some flavonoids also have been reported to interact with ABC transporters, such as P-glycoprotein, MRPI, MRP2, and cystic fibrosis transmembrane conductance regulator (16–21).

Genistein and naringenin displayed stronger interaction with BCRP than estrene (Fig. 3, A–C), and many flavones, such as acacetin, apigenin, chrysin, diosmetin, and luteolin, and some flavonols, such as kaempferide and kaempferol, demonstrated strong reversing activity of BCRP-mediated drug resistance (Fig. 3, D and E, and Fig. 4). Flavanol, flavanone, and one-half of flavonoids tested did not show BCRP-reversing activity (Fig. 4). Two glycosylated flavonoids, narigenin-7-glucoside and luteolin-4’-O-glucoside, did show anti-BCRP activity, whereas six other glycosylated flavonoids did not (Fig. 6). From these results, we speculated that the 3-hydroxyl group of the C ring might be important for BCRP-inhibitory activity, although some exceptions do exist. The flavonoids did not show growth-inhibitory effects in K562 and KB-3–1 cells at the highest concentrations used in our experiments, suggesting that they might be safely used for circumventing BCRP-mediated drug resistance in clinical practice. Glycosylated flavonoids with anti-BCRP activity
also may be useful because of their water solubility. In our preliminary animal experiments, some flavonoid aglycones were insoluble to either water or hydrophilic solvents and therefore would be difficult to administer i.v. Therefore, use of either glycosylated flavonoids or water-soluble derivatives of flavonoids would be an alternative way to develop BCRP inhibitors.

GFI20918 was first developed as a P-glycoprotein inhibitor but also was shown to be a BCRP inhibitor (22, 23). TAG-139, which we identified as a tamoxifen-derived BCRP inhibitor, also, like tamoxifen, inhibited P-glycoprotein (9). Genistein was reported to be a substrate/inhibitor of MRPL because genistein inhibited daunorubicin transport out of cells overexpressing MRPL at a concentration of 50 \( \mu \text{M} \) (20). In the present study, genistein and naringenin effectively inhibited BCRP at a concentration of 3 \( \mu \text{M} \) (Fig. 3) but showed little effect on vincristine resistance in K562/MDR cells or on VP-16 resistance in KB/MRP cells even at a concentration of 10 \( \mu \text{M} \) (Fig. 7). Therefore, these flavonoids could be specific inhibitors of BCRP.

In previous studies, we showed that estrone inhibits BCRP function but was not transported by BCRP in its native form (7, 8). In contrast, progesterone is known to inhibit the function of P-glycoprotein but is not transported by P-glycoprotein (24). In the case of genistein, K562/BCRP cells accumulated smaller amounts of [\(^3\)H]genistein than parental K562 cells (Fig. 9). Secretion of [\(^3\)H]genistein from LLC/BCRP cells was greater than from LLC-PK1 cells in transcellular transport assays (Fig. 10). TLC analysis of transported [\(^3\)H]genistein suggested that there was increased transport of genistein aglycone in LLC/BCRP cells compared with LLC-PK1 cells (Fig. 11). Intracellular accumulation of [\(^3\)H]genistein also was decreased in LLC/BCRP cells compared with levels in parental cells (data not shown). These results suggest that inhibition of BCRP-mediated drug resistance by genistein is caused by the competitive transport of genistein by BCRP. Unlike estrone and 17\(^\beta\)-estradiol, genistein would be transported in its native form but not in either sulfated or glucurononated forms (25, 26).

Another possible mechanism of BCRP inhibition by flavonoids is the interaction with the nucleotide-binding domain of BCRP because some flavonoids, including genistein, have been shown previously to interact with nucleotide-binding domain of P-glycoprotein, which was predicted to suppress ATP-hydrolysis and energy-dependent drug transport (16–18). In the case of BCRP, modulation of ATPase activity by the flavonoids should be investigated further to clarify this possibility.

The data presented here might have clinically important implications because some flavonoids effectively inhibited BCRP-mediated drug resistance at relatively low concentrations. For instance, we showed that 3 \( \mu \text{M} \) of genistein effectively circumvented BCRP-mediated drug resistance. Soybean (100 g) contains 100–200 mg isoflavones consisting of genistein, daidzein, glycitein, and their corresponding glycosides. Several groups have investigated the pharmacokinetics of soy isoflavone. A single bolus ingestion of 50 mg genistein in healthy premenopausal women was shown to result in a peak plasma concentration of 1.26 ± 0.27 \( \mu \text{M} \) at 9.33 ± 1.33 h (25). The rate of unconjugated genistein was only approximately 2–4%. However, in another report of 6-consecutive-day feeding study of 25 g soymilk powder in young adult women, the percentage of plasma aglycone genistein sampled on days 5 and 6 was 26 ± 7% of total genistein (26). In addition, glucuronide was the main metabolite in that study. Therefore, the concentration of active genistein in cancer tissues may reach sufficient level for BCRP inhibition via oral ingestion because \( \beta \)-glucuronidase activity is elevated in cancer (27). Parenteral administration may validate genistein as BCRP inhibitor. Subcutaneous injection of genistein was shown previously to enable high concentration of active genistein in mice (28).

The findings that glycosylated flavonoids naringenin-7-glucoside and luteolin-4′-O-glucoside effectively inhibited BCRP-mediated drug resistance might prove to be of great importance. These glycosylated flavonoids are well soluble in water. Because deglycosylation by intestinal enzymes precedes glucuronidation via oral routes, the i.v. injection of glycosylated flavonoids would bypass deglycosidation and retain their native structures, which are effective as BCRP inhibitors. In fact, i.v. naringenin-7-glucoside was excreted in urine mostly as its native glucoside form in a rat model (29).

Despite the promising results using flavonoids in the reversal of BCRP-mediated drug resistance, we must bear in mind that that coadministration or intake of flavonoids with BCRP-substrate antimetabolite/antitumor agents may result in the alteration of their pharmacokinetics and may increase the toxicity of the antitumor drugs in the recipient patients. In this regard, orally administered GFI20918 has been reported to increase oral bioavailability of topotecan (30).

In summary, phytoestrogens/flavonoids reverse BCRP-mediated drug resistance effectively, and these findings may bring direct and immediate clinical benefits via more effective and safer cancer chemotherapy treatments.

ACKNOWLEDGMENTS

We thank Dr. H. Esumi, National Cancer Center Research Institute East, for helpful suggestions and advice. KB/MRP cells were a gift from Dr. K. Ueda, Graduate School of Agriculture, Kyoto University. We also thank Dr. L. Greenberger and Wyeth Ayerst for providing fumitremorgin C.

REFERENCES

Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug Resistance

Yasuo Imai, Satomi Tsukahara, Sakiyo Asada, et al.

*Cancer Res* 2004;64:4346-4352.

**Updated version**
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/12/4346

**Cited articles**
This article cites 29 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/12/4346.full.html#ref-list-1

**Citing articles**
This article has been cited by 22 HighWire-hosted articles. Access the articles at:
/content/64/12/4346.full.html#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.